The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies
Stephen Lownie
102 participants
Apr 3, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to test the effect of a drug called tranexamic acid (TXA) on reducing blood loss in participants undergoing surgery to remove brain tumors. The main questions it aims to answer are: 1. Does TXA 20 mg/kg IV bolus of TXA, and 1 mg/kg/hr infusion of TXA reduce the amount of estimated blood loss during surgery? 2. Does TXA 20 mg/kg IV bolus of TXA, and 1 mg/kg/hr infusion of TXA prevent re-operation, disability or death related to bleeding inside the head during and after surgery? Participants are randomized to receive 20 mg/kg IV bolus of TXA or matching placebo within 30 minutes of start of surger, and then 1 mg/kg/hr infusion of TXA or matching from the start of surgery to end of surgery. Treatment allocation is blinded. Investigator will compare the two treatment arms to see whether there are differences in the amount of blood loss during surgery and bleeding-related complications. Investigators will also monitor for any side effects of TXA.
Eligibility
Inclusion Criteria3
- Adult male or female, between 18-80 years of age.
- Patients are scheduled to undergo a craniotomy for tumor resection.
- Patients/ Substitute Decision Maker have given written consent to participate.
Exclusion Criteria7
- Patients with known active or previous history of thromboembolic disease or deep venous thrombosis.
- Patients with known pre-existing coagulopathy such as hemophilia, Von Willebrand disease, and clotting factor deficiencies.
- Patients with renal impairment and eGFR \<60 ml/min/1.73 m2 as determined by the lab or calculated by using the Cockcroft Gault formula or end stage renal disease currently on dialysis.
- Female subjects who are pregnant or currently breastfeeding.
- Patients with Class 3 (high-risk) obesity BMI ≥ to 40.
- Patients undergoing emergency craniotomy or mini craniotomy or craniectomies.
- Patients who received embolization prior to surgery.
Interventions
Tranexamic acid 20 mg/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, for the duration of surgery. Treatment is blinded.
0.9% normal saline 20ml/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 ml/kg/hr infusion of 0.9 % sodium chloride for the duration of surgery. Treatment is blinded.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06229483